Pfizer (PFE) and Valneva SE (VALN) announced topline results from the Phase 3 VALOR Vaccine Against Lyme for Outdoor Recreationists trial of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 demonstrating: in the pre-specified analyses: efficacy of 73.2% from 28 days post-dose 4 in reducing the rate of confirmed Lyme disease cases compared to the placebo arm, efficacy of 74.8% from 1-day post-dose 4 in reducing the rate of confirmed Lyme disease cases compared to the placebo arm.
Fewer than anticipated Lyme disease cases were accrued over the study period, and the pre-determined statistical criterion was not met in the first pre-specified analysis. Given the clinically meaningful efficacy and the fact that the 95% confidence interval lower bound was above 20 in the second pre-specified analysis, Pfizer is planning submissions to regulatory authorities.
The companies entered into a collaboration and license agreement in April 2020 for the co-development of PF-07307405 and for Pfizer to manufacture and commercialize PF-07307405, assuming regulatory success.
In pre-market trading on NasdaqGS, Valneva shares are down 35 percent to $6.70.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.